Studyuncertain evidence
In alcohol use disorder and comorbid obesity, weekly semaglutide reduced heavy drinking days at 26 wk.
Annals of internal medicine·August 4, 2026·PMID 42546302
Why it mattersAlcohol use disorder in patients with obesity is common and challenging to treat. A medication that addresses both conditions could simplify management and improve outcomes, making this finding relevant for clinicians managing metabolic and addiction comorbidities.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled